Form 4: Director Edward Mathers Receives OnKure Stock Options

Director Edward T. Mathers was granted 7,650 stock options in OnKure Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Edward T. Mathers acquired 7,650 stock options in OnKure Therapeutics, Inc. (OKUR).
• The options have an exercise price of $4.30 per share.
• The grant date for these options is June 4, 2026.
• The options are set to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director continuing as a service provider through the vesting date.
• Market volatility could impact the future value of the granted options.

Future Outlook

The options vest on the earlier of June 4, 2027, or the day prior to the next annual meeting of stockholders, provided the director remains a service provider.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.
• The use of time-based vesting is a standard governance practice to ensure director retention.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the day prior to the next annual meeting of stockholders.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Director Compensation, Stock Options, Insider Transaction, Form 4